Difference of serum tumor markers in different clinical stages of elderly patients with non-small cell lung cancer and evaluation of diagnostic value
Abstract
Objective To explore the difference and diagnostic value evaluation of serum tumor markers in different clinical stages of elderly non-small cell lung cancer (NSCLC) patients.
Methods Select 100 elderly NSCLC patients admitted to our hospital from June 2018 to June 2021, collect the general data, pathology data and imaging data of the patients, and the patients were divided into I-IV clinical stages according to the International Union Against Cancer (UICC) 8th edition lung cancer TNM staging standard. Detect the subjects’ peripheral serum tumor markers, serum carcinoembryonic antigen (CEA), cytokeratin fragment 21-1 (CYFRA21-1), squamous cell carcinoma-associated antigen (SCCA), carbohydrate antigen 125 (CA125) and sugar Class antigen 199 (CA199). Compare the differences of serum CEA, CYFRA21-1, SCCA, CA125, CA199 levels in different clinical stages of elderly NSCLC patients, and the diagnostic value of the above indicators for elderly NSCLC patients was analyzed by receiver operating characteristic curve (ROC curve) and area under the curve (AUC).
Results The smoking history, differentiation degree, lymph node metastasis and tumor diameter of elderly NSCLC patients with different clinical stages are significantly different; with the increase of NSCLC disease progression, the levels of serum CEA, CYFRA21-1, SCCA, CA125, and CA199 continue to increase, and serum tumors There is a significant correlation between the markers; serum CEA, CYFRA21-1, SCCA, CA125, CA199 have diagnostic value for the clinical staging of elderly NSCLC patients.
Conclusions The elevation of serum CEA, CYFRA21-1, SCCA, CA125 and CA199 in elderly NSCLC patients is positively correlated with the degree of tumor malignancy. The detection of the above indicators is of great value for the early diagnosis and disease monitoring of elderly NSCLC.
References
[1] Tian X, Gu T, Lee M H, et al. Challenge and countermeasures for EGFR targeted therapy in non-small cell lung cancer[J]. Biochim Biophys Acta Rev Cancer,2021,1877(1):188645.
[2] Heiden B T, Eaton D J, Chang S H, et al. Assessment of Duration of Smoking Cessation Prior to Surgical Treatment of Non-small Cell Lung Cancer[J]. Ann Surg,2021.
[3] Zhang Y, Guo R, Li J, et al. Research progress on the occurrence and therapeutic mechanism of ferroptosis in NSCLC[J]. Naunyn Schmiedebergs Arch Pharmacol,2021.
[4] Tang A, Ahmad U, Raja S, et al. How Much Delay Matters? How Time to Treatment Impacts Overall Survival in Early Stage Lung Cancer[J]. Ann Surg,2021.
[5] Dall'Olio F G, Abbati F, Facchinetti F, et al. CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors[J]. Ther Adv Med Oncol,2020,12:431399262.
[6] Motono N, Iwai S, Iijima Y, et al. Operative invasiveness does not affect the prognosis of patients with non-small cell lung cancer[J]. BMC Pulm Med,2020,20(1):265.
[7] Haslam A, Kim M S, Prasad V. Overall survival for oncology drugs approved for genomic indications[J]. Eur J Cancer,2021.
[8] Chae K J, Choi H, Jeong W G, et al. The Value of the Illness-Death Model for Predicting Outcomes in Patients with NonSmall Cell Lung Cancer[J]. Cancer Res Treat,2021.
[9] Willen L, Berglund A, Bergstrom S, et al. Are older patients with non-small cell lung cancer receiving optimal care? A population-based study[J]. Acta Oncol,2021:1~9.
[10] Syed Y A, Stokes W, Rupji M, et al. Surgical Outcomes for Early-Stage Non-Small Cell Lung Cancer at Facilities with Stereotactic Body Radiation Therapy Programs[J]. Chest,2021.
[11] Tokito T, Azuma K, Yamada K, et al. Prognostic Value of Serum Tumor Markers in Patients With Stage III NSCLC Treated With Chemoradiotherapy[J]. In Vivo,2019,33(3):889~895.
[12] Zhang F, Qiu B, Ji Y, et al. Comparison of surgical difficulty in patients with resectable non-small cell lung cancer under different neoadjuvant treatment modes: a retrospective cohort study[J]. J Thorac Dis,2021,13(10):5604~5616.
[13] Syed Y A, Stokes W, Rupji M, et al. Surgical Outcomes for Early-Stage Non-Small Cell Lung Cancer at Facilities with Stereotactic Body Radiation Therapy Programs[J]. Chest,2021.
[14] Yang J, Hao R, Zhang Y, et al. Construction of circRNA-miRNA-mRNA network and identification of novel potential biomarkers for non-small cell lung cancer[J]. Cancer Cell Int,2021,21(1):611.
[15] Cifkova E, Brumarova R, Ovcacikova M, et al. Lipidomic and metabolomic analysis reveals changes in biochemical pathways for non-small cell lung cancer tissues[J]. Biochim Biophys Acta Mol Cell Biol Lipids,2021:159082.
[16] Yang Y C, Liu M H, Yang S M, et al. Bimodal Multiplexed Detection of Tumor Markers in Non-Small Cell Lung Cancer with Polymer Dot-Based Immunoassay[J]. ACS Sens,2021.
[17] Sharpnack M F, Cho J H, Johnson T S, et al. Clinical and Molecular Correlates of Tumor Mutation Burden in Non-Small Cell Lung Cancer[J]. Lung Cancer,2020,146:36~41.
[18] Rahal Z, El N S, Sinjab A, et al. Smoking and Lung Cancer: A Geo-Regional Perspective[J]. Front Oncol,2017,7:194.
[19] Gould M K, Huang B Z, Tammemagi M C, et al. Machine Learning for Early Lung Cancer Identification Using Routine Clinical and Laboratory Data[J]. Am J Respir Crit Care Med,2021,204(4):445~453.
[20] Muller M, Hoogendoorn R, Moritz R, et al. Validation of a clinical blood-based decision aid to guide immunotherapy treatment in patients with non-small cell lung cancer[J]. Tumour Biol,2021,43(1):115~127.
[21] Chen H, Fu F, Zhao Y, et al. The Prognostic Value of Preoperative Serum Tumor Markers in Non-Small Cell Lung Cancer Varies With Radiological Features and Histological Types[J]. Front Oncol,2021,11:645159.
[22] Yamanashi K, Okumura N, Yamamoto Y, et al. Comparing Part-Solid and Pure-Solid Tumors in the TNM Classification of Lung Cancer (Eighth Edition)[J]. Thorac Cardiovasc Surg,2019,67(4):306~314.
[23] Bajbouj K, Al-Ali A, Ramakrishnan R K, et al. Histone Modification in NSCLC: Molecular Mechanisms and Therapeutic Targets[J]. Int J Mol Sci,2021,22(21).
[24] Leader A M, Grout J A, Maier B B, et al. Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification[J]. Cancer Cell,2021.
[25] Qu F, Wu S, Dong H, et al. An elderly advanced non-small cell lung cancer patient harboring rare epidermal growth factor receptor mutations L861R benefited from afatinib: A case report[J]. Medicine (Baltimore),2021,100(45):e27614.
[26] Liu Z, Gao Z, Zhang M, et al. Real-World Effectiveness and Prognostic Factors Analysis of Stages I-III Non-Small Cell Lung Cancer Following Neoadjuvant Chemo-Immunotherapy or Neoadjuvant Chemotherapy[J]. Ann Thorac Cardiovasc Surg,2021.
[27] Aya F, Benegas M, Vinolas N, et al. A Pilot Study to Evaluate Early Predictive Value of Thorax Perfusion-CT in Advanced NSCLC[J]. Cancers (Basel),2021,13(21).
[28] Muller M, Hoogendoorn R, Moritz R, et al. Validation of a clinical blood-based decision aid to guide immunotherapy treatment in patients with non-small cell lung cancer[J]. Tumour Biol,2021,43(1):115~127.
[29] Lang D, Haslinger W, Akbari K, et al. Serum Tumor Marker Dynamics as Predictive Biomarkers in NSCLC Chemo-Immunotherapy and Mono-Immunotherapy Maintenance: A Registry-Based Descriptive Study[J]. Lung Cancer (Auckl),2020,11:113~121.
[30] Chen H, Fu F, Zhao Y, et al. The Prognostic Value of Preoperative Serum Tumor Markers in Non-Small Cell Lung Cancer Varies With Radiological Features and Histological Types[J]. Front Oncol,2021,11:645159.
[31] Guo L, Song B, Xiao J, et al. The Prognostic Value of Biomarkers on Detecting Non-Small Cell Lung Cancer in a Chinese Elderly Population[J]. Int J Gen Med,2021,14:5279~5286.
[32] Liu F, Ma G, Wang B, et al. Prognostic value of miR-1181 in non-small cell lung cancer and its regulatory effect on tumor progression[J]. Exp Ther Med,2021,22(5):1284.
[33] Okamoto T, Miyawaki M, Toyokawa G, et al. Clinical significance of part-solid lung cancer in the eighth edition TNM staging system[J]. Interact Cardiovasc Thorac Surg,2021.
[34] Noonan S A, Patil T, Gao D, et al. Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung[J]. J Thorac Oncol,2018,13(1):134~138.
[35] Zhao T, Mao G, Chen M. The Role of Change Rates of CYFRA21-1 and CEA in Predicting Chemotherapy Efficacy for Non-Small-Cell Lung Cancer[J]. Comput Math Methods Med,2021,2021:1951364.
[36] Yoshimura A, Uchino J, Hasegawa K, et al. Carcinoembryonic antigen and CYFRA 21-1 responses as prognostic factors in advanced non-small cell lung cancer[J]. Transl Lung Cancer Res,2019,8(3):227~234.
[37] Takeuchi A, Oguri T, Sone K, et al. Predictive and Prognostic Value of CYFRA 21-1 for Advanced Non-small Cell Lung Cancer Treated with EGFR-TKIs[J]. Anticancer Res,2017,37(10):5771~5776.
[38] Sone K, Oguri T, Nakao M, et al. CYFRA 21-1 as a Predictive Marker for Non-small Cell Lung Cancer Treated with Pemetrexed-based Chemotherapy[J]. Anticancer Res,2017,37(2):935~939.
[39] Tan Q, Huang Q, Ma G, et al. Relationship between serum tumor markers and Anaplastic Lymphoma Kinase mutations in stage IV lung adenocarcinoma in Hubei province, Central China[J]. J Clin Lab Anal,2020,34(1):e23027.
[40] Ma S, Shen L, Qian N, et al. The prognostic values of CA125, CA19.9, NSE, AND SCC for stage I NSCLC are limited[J]. Cancer Biomark,2011,10(3-4):155~162.
[41] Clevers M R, Kastelijn E A, Peters B, et al. Evaluation of Serum Biomarker CEA and Ca-125 as Immunotherapy Response Predictors in Metastatic Non-small Cell Lung Cancer[J]. Anticancer Res,2021,41(2):869~876.
[42] Wang C F, Peng S J, Liu R Q, et al. The Combination of CA125 and NSE Is Useful for Predicting Liver Metastasis of Lung Cancer[J]. Dis Markers,2020,2020:8850873.
[43] Chen Z Q, Huang L S, Zhu B. Assessment of Seven Clinical Tumor Markers in Diagnosis of Non-Small-Cell Lung Cancer[J]. Dis Markers,2018,2018:9845123.
Copyright (c) 2023 WenWen Qin, Ping Wang, CuiMin Ding, Fei Peng
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.